Paper30799404
Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.
Ahrens M and 4 others. Oncol Res Treat, 2019. Cited by 43 papers, by iCite.
Cite this record
ConductScience Library. Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options. Papers, record 30799404. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30799404
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Immunological | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Carcinoma, Renal Cell | Major topic |
| Kidney | Major topic |
| Kidney Neoplasms | Major topic |
| Costimulatory and Inhibitory T-Cell Receptors | |
| Humans | |
| Progression-Free Survival | |
| Randomized Controlled Trials as Topic |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03075423 | Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC | Background |
Source ClinicalTrials.gov
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 43 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41294834 | Recent Advances in nccRCC Classification and Therapeutic Approaches. | Cells | 2025 | https://conductscience.org/library/papers/41294834 | PubMed |
| 40895976 | Oncological Outcomes of Non-clear Cell Renal Cell Carcinomas: A Retrospective Study From a Tertiary Care Center. | Cureus | 2025 | https://conductscience.org/library/papers/40895976 | PubMed |
| 40677703 | Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions. | Front Immunol | 2025 | https://conductscience.org/library/papers/40677703 | PubMed |
| 40660314 | Kinesin-related genes stratified the prognosis and immune responses of clear cell renal cell carcinoma. | Eur J Med Res | 2025 | https://conductscience.org/library/papers/40660314 | PubMed |
| 39743997 | Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis. | Front Oncol | 2024 | https://conductscience.org/library/papers/39743997 | PubMed |
| 39707614 | Exploiting NRF2-ARE pathway activation in papillary renal cell carcinoma. | Int J Cancer | 2025 | https://conductscience.org/library/papers/39707614 | PubMed |
| 39589483 | [Non-clear cell renal cell carcinoma]. | Urologie | 2024 | https://conductscience.org/library/papers/39589483 | PubMed |
| 39512820 | Long non-coding RNAs: regulators of autophagy and potential biomarkers in therapy resistance and urological cancers. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39512820 | PubMed |
| 39252678 | Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. | Health Technol Assess | 2024 | https://conductscience.org/library/papers/39252678 | PubMed |
| 38434237 | The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma. | Ther Adv Urol | 2024 | https://conductscience.org/library/papers/38434237 | PubMed |
| 37849802 | The stratification and prognostic importance of molecular and immune landscapes in clear cell renal cell carcinoma. | Front Oncol | 2023 | https://conductscience.org/library/papers/37849802 | PubMed |
| 37686629 | Advanced Non-Clear Cell Renal Cell Carcinoma Treatments and Survival: A Real-World Single-Centre Experience. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37686629 | PubMed |
| 37455214 | Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808. | Clin Genitourin Cancer | 2023 | https://conductscience.org/library/papers/37455214 | PubMed |
| 36661719 | Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature. | Curr Oncol | 2023 | https://conductscience.org/library/papers/36661719 | PubMed |
| 36275783 | Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy. | Cancer Manag Res | 2022 | https://conductscience.org/library/papers/36275783 | PubMed |
| 36238848 | miR-5590-3p inhibits the proliferation and metastasis of renal cancer cells by targeting ROCK2 to inhibit proliferation, migration and invasion. | Oncol Lett | 2022 | https://conductscience.org/library/papers/36238848 | PubMed |
| 35326557 | Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35326557 | PubMed |
| 35223991 | CircRNAs as Novel Biomarkers and Therapeutic Targets in Renal Cell Carcinoma. | Front Mol Biosci | 2022 | https://conductscience.org/library/papers/35223991 | PubMed |
| 35210307 | Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/35210307 | PubMed |
| 35061242 | Immune checkpoint inhibitor-associated myocarditis : Case reports and a review of the literature. | Neth Heart J | 2022 | https://conductscience.org/library/papers/35061242 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30799404
GET https://conductscience.org/api/papers/v1/30799404/cited_by?page=2